Other Events ·
Incannex Healthcare Inc. announced the commencement of patient dosing in its DReAMzz Phase 2 dose-optimization study…
IXHLIncannex Healthcare Inc.
Incannex Healthcare Inc. announced the commencement of patient dosing in its DReAMzz Phase 2 dose-optimization study for IHL-42X, a combination therapy for obstructive sleep apnea. The U.S. Patent and Trademark Office granted a composition patent for IHL-42X with an expiry date of July 9, 2040. As of August 31, 2026, the company reported approximately $70 million in cash and no debt, bolstered by over A$11.2 million in non-dilutive capital received during 2026. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications.